Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ozanimod for Moderate to Severe Active Crohn's Disease – Induction (Phase 3)
CTR20211103Phase 3Completed
- Sponsor
- Celgene Corporation
- Start
- May 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of ozanimod in Crohn's disease, sponsored by Celgene Corporation. Started May 2021; status: completed.
02
Drugs
ozanimod
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on CTR20211103.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20211103.